Title:
NON-NATURAL NUCLEIC ACID LIGAND, USES THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2023/014192
Kind Code:
A1
Abstract:
One aspect of the present disclosure relates to a novel non-natural nucleic acid ligand that binds to human serum albumin (HSA), and to uses thereof. The novel non-natural nucleic acid ligand may include the nucleic acid sequence of SEQ ID NO: 8 (CAGG6CGAGC6G6ACGCG6G6G6GACC) [wherein the moiety indicated by 6 is 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine (Nap-dU)]. Meanwhile, one aspect of the present disclosure relates to a pharmaceutical composition for treating cancer, comprising a novel non-natural nucleic acid ligand that binds to human serum albumin as an active ingredient. The pharmaceutical composition exhibits excellent effects in the treatment of cancer.
Inventors:
LEE JUNG HWAN (KR)
LEE JONGOOK (KR)
PARK HANSEUL (KR)
LEE SE NA (KR)
LEE JONGOOK (KR)
PARK HANSEUL (KR)
LEE SE NA (KR)
Application Number:
PCT/KR2022/011718
Publication Date:
February 09, 2023
Filing Date:
August 05, 2022
Export Citation:
Assignee:
INTEROLIGO CORP (KR)
International Classes:
A61K48/00; A61K31/7088; A61K47/42; A61P35/00; C12N15/113
Domestic Patent References:
| WO2018048815A1 | 2018-03-15 | |||
| WO2020115072A1 | 2020-06-11 | |||
| WO1991019813A1 | 1991-12-26 |
Foreign References:
| KR20170070022A | 2017-06-21 | |||
| US20180044738A1 | 2018-02-15 | |||
| KR20210084278A | 2021-07-07 | |||
| KR20190126356A | 2019-11-11 | |||
| US8969318B2 | 2015-03-03 | |||
| US5475096A | 1995-12-12 | |||
| US5270163A | 1993-12-14 |
Other References:
ZHANG ET AL.: "Recent Advances in Aptamer Discovery and Applications", MOLECULES, vol. 24, 2019, pages 941
ZHOU, J.ROSSI, J.: "Aptamers as Targeted Therapeutics: Current Potential and Challenges", NAT. REV. DRUG DISCOVERY, vol. 16, 2017, pages 181 - 202, XP055649283, DOI: 10.1038/nrd.2016.199
DOUGAN, H.LYSTER, D. M.VO, C. V.STAFFORD, A.WEITZ, J. I.HOBBS, J. B.: "Extending the Lifetime of Anticoagulant Oligodeoxynucleotide Aptamers in Blood", NUCL. MED. BIOL., vol. 27, 2000, pages 289 - 297, XP004205326, DOI: 10.1016/S0969-8051(99)00103-1
POVSIC, T. J. ET AL.: "Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer", J ALLERGY CLIN IMMUNOL, vol. 138, no. 6, 2016, pages 1712, XP029840968, DOI: 10.1016/j.jaci.2016.04.058
M. M. SOLDEVILLAH. VILLANUEVAF. PASTOR: "Aptamers: A Feasible Technology in Cancer Immunotherapy", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2016
ZHOU, J.ROSSI, J.: "Aptamers as Targeted Therapeutics: Current Potential and Challenges", NAT. REV. DRUG DISCOVERY, vol. 16, 2017, pages 181 - 202, XP055649283, DOI: 10.1038/nrd.2016.199
DOUGAN, H.LYSTER, D. M.VO, C. V.STAFFORD, A.WEITZ, J. I.HOBBS, J. B.: "Extending the Lifetime of Anticoagulant Oligodeoxynucleotide Aptamers in Blood", NUCL. MED. BIOL., vol. 27, 2000, pages 289 - 297, XP004205326, DOI: 10.1016/S0969-8051(99)00103-1
POVSIC, T. J. ET AL.: "Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer", J ALLERGY CLIN IMMUNOL, vol. 138, no. 6, 2016, pages 1712, XP029840968, DOI: 10.1016/j.jaci.2016.04.058
M. M. SOLDEVILLAH. VILLANUEVAF. PASTOR: "Aptamers: A Feasible Technology in Cancer Immunotherapy", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2016
Attorney, Agent or Firm:
CHANG, Duck Soon et al. (KR)
Download PDF: